CTOs on the Move

Affitech USA

www.affitech.com

 
Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.affitech.com
  • 1945 Arbol Grande
    Walnut Creek, CA USA 94595
  • Phone: 925.935.9803

Executives

Name Title Contact Details

Similar Companies

Biota Pharmaceuticals

Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 and 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.

Diagnose Early

Diagnose Early Corp is a biotechnology company that specializes in non-invasive breath biopsy health data platform powered by AI. They are commercializing diagnostics for cancer, neurological, and infectious diseases, and are in clinical trials at Stan...

Woodside Senior Communities

Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextImage Medical

NextImage Medical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.